Original Article

Incidence and antibiotic susceptibility profile of uropathogenic Escherichia coli positive for extended spectrum β-lactamase among HIV/AIDS patients in Awka metropolis, Nigeria

Abstract

Background and Objectives: This study investigated the incidence and antibiotic susceptibility profile of extended spectrum β-lactamase (ESBL) producing uropathogenic Escherichia coli recovered from HIV/AIDS patients in Awka metropolis, Nigeria.
Materials and Methods: A total of 363 urine samples were bacteriologically analyzed for the isolation of E. coli isolates which were further characterized using standard microbiology techniques. The isolated uropathogenic E. coli was tested for susceptibility to a range of clinically important antibiotics using the modified disk diffusion technique. All E. coli isolates were phenotypically screened for ESBL production using the combined disk technique, and strains which were positive were further confirmed for the presence of ESBL genes using PCR technique.
Results: A total 160 (44.1%) non-duplicate isolates were bacteriologically confirmed to be uropathogenic E. coli (UPEC). The E. coli isolates showed reduced susceptibility to important antibiotics including ceftazidime (76.88%), cefuroxime (77.5%), cefixime (61.88%), amoxicillin-clavulanic (32.5%) and ciprofloxacin (34.38%). Twenty-seven of the UPEC isolates were phenotypically confirmed to be ESBL producers. PCR test confirmed some important genes mediating ESBL production in Gram negative bacteria including blaTEM (5.0%) and blaCTX-M-15 (6.9%) genes.
Conclusion: We report a high prevalence of ESBL producers among HIV/AIDS patients in Awka, Nigeria. This result is important as antibiotic resistance (ABR) particularly those mediated by multidrug resistant bacteria as reported in this current study could complicate treatment outcome, worsen the individual’s health, and even increase cost of treatment and hospitalization. It is therefore important to lookout for ESBL positive UPEC amongst HIV/AIDS patients in Nigeria.

1. Ejikeugwu C, Ikegbunam M, Ugwu C, Eze P, Iroha I, Charles E. Phenotypic detection of Klebsiella pneumoniae strains-producing Extended Spectrum β-Lactamase (ESBL) enzymes. Sch Acad J Biosci 2013; 1: 20-23.
2. Ekwealor PA, Ugwu MC, Ezeobi I, Amalukwe G, Ugwu BC, Okezie U, et al. Antimicrobial evaluation of bacterial isolates from urine specimen of patients with complaints of urinary tract infections in Awka, Nigeria. Int J Microbiol 2016; 2016: 9740273.
3. Ugwu MC, Shariff M, Nnajide CM, Beri K, Okezie UM, Iroha IR, Esimone CO. Phenotypic and molecular characterization of β-Lactamases among Enterobacterial Uropathogens in South-Eastern Nigeria. Can J Infect Dis Med Microbiol 2020; 2020: 5843904.
4. Iregbu KC, Nwajiobi-Princewill PI. Urinary tract infections in a tertiary hospital in Abuja, Nigeria. Afr J Clin Exp Microbiol 2013; 14: 169-173.
5. Abujnah AA, Zorgani A, Sabri MA, El-Mohammady H, Khalek RA, Ghenghesh KS. Multidrug resistance and extended-spectrum b-lactamases genes among Escherichia coli from patients with urinary tract infections in Northwestern Libya. Libyan J Med 2015; 10: 26412.
6. Elsayed TI, Ismail HA, Elgamal SA, Gad AH. The Occurrence of multidrug resistant E. coli which produce ESBL and cause urinary tract infections. J Appl Microbiol Biochem 2017; l: 1-8.
7. Xavier TF, Auxilia A, Auxilia A, Kannan M. Isolation and characterization of UTI pathogens from HIV positive patients of Karur district, Tamil Nadu, India. Int J Curr Microbiol Appl Sci 2015; 4: 558-563.
8. Padmavathy K, Padma K, Rajasekaran S. Multidrug resistant CTX-M-producing Escherichia coli: A growing threat among HIV patients in India. J Pathog 2016; 2016: 4152704.
9. Jadhav S, Hussain A, Devi S, Kumar A, Parveen S, Gandham N, et al. Virulence characteristics and genetic affinities of multiple drug resistant uropathogenic Escherichia coli from a semi urban locality in India. PLoS One 2011; 6(3): e18063.
10. Waheed A, Saleem S, Shahzad N, Akhtar J, Saeed M, Jameel I, et al. Prevalence of extended spectrum β-lactamase SHV and OXA producing gram negative bacteria at tertiary care hospital of Lahore, Pakistan. Pakistan J Zool 2019; 51: 2345-2351.
11. Malande OO, Nuttall J, Pillay V, Bamford C, Eley B. A ten-year review of ESBL and non-ESBL Escherichia coli bloodstream infections among children at a tertiary referral hospital in South Africa. PLoS One 2019; 14(9): e0222675.
12. Cheesbrough M (2004). District laboratory practice in tropical countries. 2nd ed. Cambridge University Press. UK.
13. Wayne PA (2017). Clinical and Laboratory Standards Institute (CLSI). Performance standards for Antimicrobial susceptibility testing. 17th ed. CLSI supplement M100.
14. Ejikeugwu PC, Ugwu CM, Araka CO, Gugu T, Iroha I, Adikwu M, et al. Imipenem and meropenem resistance amongst ESBL producing Escherichia coli and Klebsiella pneumonia clinical isolates. Int Res J Microbiol 2012; 3: 339-344.
15. Ejikeugwu C, Iroha I, Amaechi CO, Ugwu M, Eze P, Iroha CS, et al. Multiple antibiotic resistance, antibiogram and phenotypic detection of Metallo-Beta-Lactamase (MBL) from Escherichia coli of poultry origin. J Appl Microbiol Biochem 2017; 1: 1-5.
16. Zakka S, Oluwatosin OC, Cosmas EC, John S, Rebecca EF, Isa BE. Prevalence of urinary tract infection in HIV patients on antiretroviral drugs in Jos Metropolis, Nigeria. World J Pub Health 2018; 3: 57-60.
17. Skrzat-Klapaczyńska A, Matłosz B, Bednarska A, Paciorek M, Firląg-Burkacka E, Horban A. Factors associated with urinary tract infections among HIV-1 infected patients. PLoS One 2018; 13(1): e0190564.
18. Kanu AM, Mgbajiaka N, Abadom N. Prevalence of urinary tract infection among HIV patients in Aba, Nigeria. Int J Infect Dis 2016; 45: S1-229.
19. Ugwu MC, Ikegbunam MN, Nduka SO, Attama AA, Ibezim EC, and Esimone CO. Molecular characterization and efficacy of antibiotic combinations on multiple antibiotic resistant Staphylococcus aureus isolated from nostrils of healthy human volunteers. J Pharm Sci Res 2013; 5: 26-32.
20. Ejikeugwu C, Ugwu M, Iroha I, Gugu T, Duru C, Eze P, et al. Detection and antimicrobial susceptibility of some Gram-negative bacteria producing carbapenemases and extended spectrum β-Lactamases. Int J Microbiol Immunol Res 2013; 2: 064-069.
21. Zenati F, Barguigua A, Nayme K, Benbelaïd F, Khadir A, Bellahsene C, et al. Characterization of uropathogenic ESBL-producing Escherichia coli isolated from hospitalized patients in western Algeria. J Infect Dev Ctries 2019; 13: 291-302.
22. Bali EB, Acik L, Sultan N. Phenotypic and molecular characterization of SHV, TEM, CTX-M and extended-spectrum beta-lactamase produced by Escherichia coli, Acinetobacter baumannii and Klebsiella isolates in a Turkish hospital. Afr J Microbiol Res 2010; 4: 650-654.
23. Bailey JK, Pinyon JL, Anantham S, Hall RM. Commensal Escherichia coli of healthy humans: A reservoir for antibiotic‐resistance determinants. J Med Microbiol 2010; 59: 1331-1339.
24. Padmavathy K, Padma K, Rajasekaran S. Extended spectrum β- lactamase/AmpC-producing uropathogenic Escherichia coli from HIV patients: do they have a low virulence score? J Med Microbiol 2013; 62: 345-351.
Files
IssueVol 14 No 3 (2022) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijm.v14i3.9770
Keywords
HIV; Drug resistance; Uropathogenic Escherichia coli; Antimicrobial resistance; Extended-spectrum β-lactamase
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Nwokolo C, Ugwu M, Ejikeugwu C, Iroha I, Esimone C. Incidence and antibiotic susceptibility profile of uropathogenic Escherichia coli positive for extended spectrum β-lactamase among HIV/AIDS patients in Awka metropolis, Nigeria. Iran J Microbiol. 2022;14(3):334-340.